/PRNewswire/ The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com s.
The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful and lucrative new obesity medicines. Zepbound's active ingredient tirzepatide was previously approved under the trade name Mounjaro, a diabetes control drug also made by Eli Lilly.
Access to “miracle” weight loss drugs is poised to become more widespread, after British and American pharmaceuticals regulators gave approval to a new competitor to Wegovy.